Thalidomide update: regulatory aspects.
Kelsey
F O
FO
Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857.
D000014:Abnormalities, Drug-Induced; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007880:Legislation, Drug; D011247:Pregnancy; D013723:Teratogens; D013792:Thalidomide / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration; D014944:World Health Organization
D013723:Teratogens; D013792:Thalidomide